Cancers, Free Full-Text

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

Kidney Cancer Text · Free Stock Photo

𝓙𝓾𝓵𝓲𝓪𝓷𝓮_𝓛𝓲𝓫𝓮𝓻𝓽𝓸 (@JulianeLiberto) / X

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.

from Flow Cytometry to Cytomics, Page 2

IASLC International Association for the Study of Lung Cancer

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Time trial: A prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers – topic of research paper in Clinical medicine. Download scholarly

Thoracic Cancer - Wiley Online Library

National Comprehensive Cancer Network - Home